达罗他胺在非转移性去势抵抗性前列腺癌合并症及合并用药患者中的疗效与安全性:随机3期ARAMIS试验的事后分析
ARAMIS试验事后分析,按合并症数目和合并用药数目对非转移性去势抵抗性前列腺癌患者分层,评估达罗他胺(n=955)与安慰剂(n=554)的总生存和不良事件。合并症≤6和>6者达罗他胺较安慰剂均提高总生存(HR 0.65和0.73),合并用药≤10和>10者亦然(HR 0.76和0.66),不良事件发生率与安慰剂相似。
要点
- 合并症≤6和>6者达罗他胺较安慰剂提高总生存,HR分别为0.65和0.73。
- 合并用药≤10和>10者达罗他胺较安慰剂提高总生存,HR分别为0.76和0.66。
- 各亚组中达罗他胺的不良事件及导致停药的不良事件发生率与安慰剂相似。
核心结论
- 达罗他胺的总生存获益和安全性在合并症或合并用药数目多的患者中与总体ARAMIS人群一致。
研究设计与样本
- ARAMIS随机3期试验的事后分析,非转移性去势抵抗性前列腺癌患者按2:1随机接受达罗他胺(n=955)或安慰剂(n=554),同时继续雄激素剥夺治疗。
主要发现
- 合并症和合并用药的中位数目分别为6和10,41.6%的患者合并症>6种,48.8%的患者合并用药>10种。
- 合并症≤6和>6者,达罗他胺较安慰剂提高总生存,HR分别为0.65和0.73;心血管、代谢及其他合并症亚组获益一致(HR范围0.39-0.88)。
- 合并用药≤10和>10者,达罗他胺较安慰剂亦提高总生存,HR分别为0.76和0.66;各药物类别获益一致(HR范围0.45-0.80)。
- 按合并症和合并用药数目划分的各亚组中,达罗他胺的不良事件及导致停药的不良事件发生率与安慰剂相似。
关键数值与推荐
- 合并症≤6者达罗他胺较安慰剂总生存HR 0.65,>6者HR 0.73。
- 合并用药≤10者达罗他胺较安慰剂总生存HR 0.76,>10者HR 0.66。
- 合并症亚组(心血管、代谢及其他)总生存HR范围0.39-0.88。
- 合并用药类别亚组总生存HR范围0.45-0.80。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the Androgen Receptor Antagonizing Agent for Metastasis-free Survival (ARAMIS) trial, darolutamide significantly improved median metastasis-free survival by nearly 2 years and reduced the risk of death by 31% versus placebo, with a favourable safety/tolerability profile. This post hoc analysis of ARAMIS evaluated efficacy and safety in patients by number of comorbidities and concomitant medications. METHODS: Patients with nmCRPC were randomised 2:1 to darolutamide (n = 955) or placebo (n = 554) while continuing androgen-deprivation therapy. Overall survival (OS) and treatment-emergent adverse events (TEAEs) were evaluated in subgroups by median numbers of ongoing comorbidities and concomitant medications. HRs were determined from univariate analysis using Cox regression. FINDINGS: Median numbers of comorbidities and concomitant medications were 6 and 10, respectively, with 41.6% of patients having >6 comorbidities and 48.8% taking >10 concomitant medications. For patients with ≤ 6 and >6 comorbidities, darolutamide increased OS versus placebo (hazard ratio [HR] 0.65 and 0.73, respectively), and this benefit was consistent for cardiovascular, metabolic, and other comorbidities (HR range: 0.39-0.88). For patients taking ≤ 10 and >10 concomitant medications, increased OS was also observed with darolutamide versus placebo (HR 0.76 and 0.66, respectively), and the benefit was consistent across medication classes (HR range: 0.45-0.80). Incidences of TEAEs and TEAEs leading to treatment discontinuation with darolutamide were similar to placebo across subgroups by numbers of comorbidities and concomitant medications. CONCLUSIONS: The OS benefit and safety of darolutamide remained consistent with that observed in the overall ARAMIS population, even in patients with high numbers of comorbidities or concomitant medications. GOV REGISTRATION: NCT02200614. TWEETABLE ABSTRACT: Darolutamide increased overall survival versus placebo, and incidences of most adverse events were similar between treatments in patients with ≤ 6 or >6 comorbidities and those taking ≤ 10 or >10 concomitant medications.
引用
- Fizazi K, Shore ND, Smith M, et al. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Eur J Cancer. 2023. PMID: 37660438. doi:10.1016/j.ejca.2023.113258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。